Form 4: Acrivon Therapeutics Executive Granted Stock Options

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, was granted stock options for 45,045 shares on March 1, 2024.

Summary

• Erick Gamelin, the Chief Development Officer of Acrivon Therapeutics, was granted stock options to purchase 45,045 shares of common stock.
• The options have an exercise price of $5.70 per share.
• The options vest over time, with 25% vesting on March 1, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The vesting is contingent upon Mr. Gamelin's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the executive leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The stock options will vest over time, contingent on the executive's continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and the remainder over three years is fairly typical for such grants.
• The exercise price of $5.70 is a fixed price at the time of the grant, and the value of the options will depend on the future stock price of Acrivon Therapeutics.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Acrivon Therapeutics, ACRV, Erick Gamelin, vesting